First-line continuous or intermittent capecitabine vs cyclophosphamide + methotrexate + fluorouracil in women with advanced breast cancer who were unsuitable for more intensive treatment

Trial Profile

First-line continuous or intermittent capecitabine vs cyclophosphamide + methotrexate + fluorouracil in women with advanced breast cancer who were unsuitable for more intensive treatment

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Dec 2011

At a glance

  • Drugs Capecitabine; Cyclophosphamide; Fluorouracil; Methotrexate
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Oct 2011 Results published in the Journal of Clinical Oncology.
    • 27 Mar 2010 Results from an analysis of three trials presented at the 7th European Breast Cancer Conference
    • 13 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top